RFC2

Across TCGA pan-cancer cohorts, RFC2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RFC2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RFC2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RFC2 is over-expressed in tumor.

HNSC, CCRCC, and LSCC are the cancer types where RFC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.840	<.001	11	view →
CCRCC	Female	II,III,IV	+0.274	<.001	11	view →
LSCC	Male	II,III,IV	+0.870	<.001	9	view →
LUAD	Male	III,IV	+0.385	<.001	9	view →
COAD	Female	All	+0.312	<.001	9	view →
PDAC	All	III,IV	+0.376	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RFC2–HNSC

Open the HNSC breakdown →